ABSTRACT

OBJECTIVES: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19.

MATERIALS AND METHODS: We conducted a prospective single-center study among patients hospitalized for COVID-19 between March and May 2020. Patients with residual symptoms or admitted into intensive care units were investigated 4 months after discharge by a chest CT (CCT) and pulmonary function tests (PFTs). The primary endpoint was the rate of persistent radiological fibrotic lesions after 4 months. Secondary endpoints included further CCT evaluation at 9 and 16 months, correlation of fibrotic lesions with clinical and PFT evaluation, and assessment of predictive factors.

RESULTS: Among the 1151 patients hospitalized for COVID-19, 169 patients performed a CCT at 4 months. CCTs showed pulmonary fibrotic lesions in 19% of the patients (32/169). These lesions were persistent at 9 months and 16 months in 97% (29/30) and 95% of patients (18/19) respectively. There was no significant clinical difference based on dyspnea scale in patients with pulmonary fibrosis. However, PFT evaluation showed significantly decreased diffusing lung capacity for carbon monoxide (p < 0.001) and total lung capacity (p < 0.001) in patients with radiological lesions. In multivariate analysis, the predictive factors of radiological pulmonary fibrotic lesions were pulmonary embolism (OR = 9.0), high-flow oxygen (OR = 6.37), and mechanical ventilation (OR = 3.49).

CONCLUSION: At 4 months, 19% of patients investigated after hospitalization for COVID-19 had radiological pulmonary fibrotic lesions; they persisted up to 16 months.

CLINICAL RELEVANCE STATEMENT: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. The prevalence of persisting lesions after COVID-19 remains unclear. We assessed this prevalence and predictive factors leading to fibrotic lesions in a large cohort. The respiratory clinical impact of these lesions was also assessed.

KEY POINTS: • Nineteen percent of patients hospitalized for COVID-19 had radiological fibrotic lesions at 4 months, remaining stable at 16 months. • COVID-19 fibrotic lesions did not match any infiltrative lung disease pattern. • COVID-19 fibrotic lesions were associated with pulmonary function test abnormalities but did not lead to clinical respiratory manifestation.

PMID:37572192 | DOI:10.1007/s00330-023-10044-0

➖ Sent by @TheFeedReaderBot ➖

17:17

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

17:17

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

17:17

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

17:17

PubMed articles on: Cancer & VTE/PE

Life-threatening perioperative complications among older adults with spinal metastases: An analysis based on a nationwide inpatient sample of the US

J Geriatr Oncol. 2023 Aug 3;14(7):101597. doi: 10.1016/j.jgo.2023.101597. Online ahead of print.

ABSTRACT

INTRODUCTION: We aimed to investigate the prognostic determinants of life-threatening and fatal complications in patients <80

MATERIALS AND METHODS: Based on data between 2005 and 2018 extracted from National Inpatient Sample as the largest longitudinal hospital inpatient databases in the United States, statistical analyses were performed to identify prognostic factors (age, sex, household income, insurance status, major comorbidities, primary site of malignancy, types of surgery, surgical approaches, types of hospital admission, and hospital-related characteristics) for major and fatal perioperative complications among older adult patients.

RESULTS: A total of 31,925 patients aged ≥ 20y who were undergoing surgery for spinal metastasis were identified (< 80 y: n = 28,448; ≥ 80 y: n = 35,37). After adjustment, age ≥80 y was significantly associated with greater risk of perioperative cardiac arrest (adjusted odds ratio [aOR]: 1.34, 95% confidence interval [CI]: 1.03-1.73) and acute kidney injury (AKI) (aOR: 1.23, 95% CI: 1.07-1.41) but lower risk of venous thromboembolic event (VTE) (aOR: 0.80, 95% CI: 0.66-0.96) than <80y.<80<80<80<80y,

DISCUSSION: This study identifies a list of independent risk factors for the presence of life-threatening complications among patients <80

PMID:37542948 | DOI:10.1016/j.jgo.2023.101597

➖ Sent by @TheFeedReaderBot ➖

17:17

In reply to this message

PubMed articles on: Cancer & VTE/PE

High risk of rehospitalization within one year following a pulmonary embolism-Insights from the Danish nationwide registries from 2000-2020

Eur Heart J Qual Care Clin Outcomes. 2023 Aug 4:qcad046. doi: 10.1093/ehjqcco/qcad046. Online ahead of print.

ABSTRACT

AIM: To identify the absolute risk, causes and factors associated with rehospitalization within 1 year of discharge with a pulmonary embolism (PE).

METHODS AND RESULTS: Using the Danish nationwide registries, all patients admitted with a first-time PE between 2000 and 2020 and discharged alive were included. Subsequent hospitalizations were categorized and crude cumulative incidences, were used to estimate the absolute risk (AR) of any rehospitalization and specific causes of rehospitalizations. Risk factors for rehospitalization were investigated using cause specific Cox regression models.A total of 55 201 patients were identified. The median age of the study population was 70 years (inter quartile range: 59;79), and the most prevalent comorbidities were cancer (29.3%) and ischemic heart disease (12.7%). The 1-year AR of any rehospitalization after discharge with a PE was 48.6% (95% confidence interval (CI); 48.2%-48.8%). The most common cause for being rehospitalized was due to respiratory disease (1-year AR: 9.5% (95% CI: 9.3%-9.8%)), followed by cardiovascular disease (1-year AR: 6.3% (95% CI: 5.9%-6.5%)), cancer (1-year AR: 6.0% (95% CI: 5.8%-6.4%)), venous thromboembolism (1-year AR: 5.2% (95% CI: 5.0%-5.2%)), and symptom diagnoses (1-year AR: 5.2% (95%CI: 5.0%-5.4%)). Factors that were associated with an increased risk of rehospitalization were cancer, liver disease, chronic obstructive pulmonary disease, chronic kidney disease, and immobilization.

CONCLUSION: Patients with PE have a high risk of rehospitalization, with almost half of patients being rehospitalized within 1 year. Identification of high-risk patients may help target interventions aiming at reducing the risk of rehospitalization.

PMID:37541959 | DOI:10.1093/ehjqcco/qcad046

➖ Sent by @TheFeedReaderBot ➖

17:17

In reply to this message

PubMed articles on: Cancer & VTE/PE

Multiple Myeloma in Adolescent and Young Adults: An ASCO CancerLinQ and SEER Analysis

Clin Lymphoma Myeloma Leuk. 2023 Jul 28:S2152-2650(23)00215-X. doi: 10.1016/j.clml.2023.07.005. Online ahead of print.

ABSTRACT

BACKGROUND: Multiple myeloma (MM) is exceedingly rare in adolescents and young adults (AYAs) < 45 years of age.

METHODS: Real-world data from ASCO's CancerLinQ DiscoveryⓇ (CLQD) MM dataset and SEER were utilized to characterize demographics and outcomes of AYA MM patients in the United States in the modern treatment era. Frequencies of SPMs, VTEs, and infections were assessed, as were OS and cause of death.

RESULTS: A total of 1946 AYA MM patients from SEER and 1334 from CancerLinQ were included. In terms of SPMs, AYAs were more likely to develop ALL (RR 2.6, P = .003) and AML (RR 1.7, P = .034), and less likely to develop nonmelanoma skin cancer (RR 0.2, P = .001) and prostate cancer (RR 0.1, P = .013) than MM patients ≥ 45. AYAs were at lower risk of VTE (RR 0.75, P = .002) and slightly higher risk of infections (RR 1.11, P = .002). Median OS among AYA MM patients was significantly longer than MM patients ≥ 45 in both datasets. In the SEER cohort, female sex (HR 0.74, P = .003), non-Hispanic ethnicity (HR 0.73, P = .005), and annual household income ≥ $65,000 per year (HR 0.67, P = .001) were associated with lower hazards of mortality. In the CLQD cohort, OS was significantly influenced by female sex (HR 0.6, P = .048). Race did not have a statistically significant impact OS in either cohort. Most AYAs died of MM (68.3%), other primary malignancy (7.5%, mostly leukemia), and cardiovascular events (5.2%). Infections accounted for 3.2% of deaths.

CONCLUSION: This analysis highlights some unique characteristics of AYA MM patients in the United States in the modern era.

PMID:37541820 | DOI:10.1016/j.clml.2023.07.005

➖ Sent by @TheFeedReaderBot ➖

17:17

In reply to this message

PubMed articles on: Cancer & VTE/PE

Venous Thromboembolism: The Need for Transitions of Care

Med Clin North Am. 2023 Sep;107(5):883-894. doi: 10.1016/j.mcna.2023.05.001. Epub 2023 Jun 26.

ABSTRACT

The Centers for Disease Control and Prevention estimates that approximately 900,000 patients are diagnosed with venous thromboembolism (VTE) annually in the United States leading to approximately 548,000 hospitalizations and 100,000 deaths. Approximately 274 people die daily in the United States from VTE. The numbers are staggering with 1 person dying every 5 minutes! There are more deaths annually in the United States from VTE than breast cancer (41,000), AIDS (16,000), and motor vehicle accidents (32,000) combined! VTE is recognized as a leading cause of preventable hospital deaths and a leading cause of maternal deaths.

PMID:37541714 | DOI:10.1016/j.mcna.2023.05.001

➖ Sent by @TheFeedReaderBot ➖

17:17

PubMed articles on: Cancer & VTE/PE

Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study

Cancer Immunol Immunother. 2023 Aug 4. doi: 10.1007/s00262-023-03508-1. Online ahead of print.